--- title: "Today, the drugs developed by Astrazeneca and Sanofi for the prevention of infant RSV infection have been approved in China." description: "The drug Levoi® (nirsevimab), jointly developed by AstraZeneca and Sanofi, has been approved for market by the China National Medical Products Administration. This drug can prevent infant RSV infectio" type: "news" locale: "en" url: "https://longbridge.com/en/news/105271816.md" published_at: "2024-01-02T11:14:06.000Z" --- # Today, the drugs developed by Astrazeneca and Sanofi for the prevention of infant RSV infection have been approved in China. > The drug Levoi® (nirsevimab), jointly developed by AstraZeneca and Sanofi, has been approved for market by the China National Medical Products Administration. This drug can prevent infant RSV infection, which is one of the main causes of infant hospitalization. Nirsevimab has already been approved in the European Union and the United States, and is expected to be launched in China in 2024-2025. AstraZeneca and Sanofi have collaborated on the development, production, and commercialization of this drug. Zhitong App learned today that Astrazeneca and Sanofi have announced the official approval and launch of their jointly developed and commercialized long-acting monoclonal antibody, Nirsevimab, by the China National Medical Products Administration. This drug is used to prevent lower respiratory tract infections (LRTIs) caused by respiratory syncytial virus (RSV) in newborns and infants. RSV is a common and highly contagious seasonal virus that is the most common cause of lower respiratory tract infections in infants, such as bronchiolitis and pneumonia, and is also one of the main reasons for infant hospitalization. Data shows that RSV ranks among the top three pathogens causing viral respiratory infections in children and may lead to mixed outbreaks of various respiratory viruses. It is reported that China is one of the countries with a high prevalence of RSV worldwide. Nirsevimab is expected to be launched in China during the RSV infection season in 2024-2025. Nirsevimab was approved in the European Union in October 2022 and subsequently received approval from the U.S. Food and Drug Administration (FDA) in July 2023 based on the unanimous recommendation of the Antimicrobial Drugs Advisory Committee. Currently, the marketing applications for Nirsevimab submitted in Japan and several other markets are also under review. AstraZeneca and Sanofi announced their collaboration on the development and commercialization of Nirsevimab in March 2017. Under the terms of the agreement, AstraZeneca is responsible for product development and production, while Sanofi is responsible for commercialization and revenue measurement. Both companies share costs and profits in all regions except the United States. The revenue AstraZeneca receives based on this agreement is classified as alliance revenue and collaboration revenue in the company's financial statements. ### Related Stocks - [SNYNF.US - Sanofi](https://longbridge.com/en/quote/SNYNF.US.md) - [AZN.UK - AstraZeneca PLC](https://longbridge.com/en/quote/AZN.UK.md) - [SNY.US - Sanofi](https://longbridge.com/en/quote/SNY.US.md) - [TBIO.US - Telesis Bio](https://longbridge.com/en/quote/TBIO.US.md) - [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 富衞香港：25 年上半年新業務年度化保費按年升 90% | 富衞香港公佈 2025 年上半年新業務年度化保費按年升 90%，優於行業平均升幅 39%。新業務首年保費增長 128%，排名全港第二。各分銷渠道均實現雙位數增長，專屬代理人渠道升 69%，銀行保險渠道升 53%，經紀渠道升 291%，網上及 | [Link](https://longbridge.com/en/news/276418423.md) | | 石四藥 (2005) 發盈警料去年盈利倒退 45 至 60% | 石四藥集團發盈警，預期截至去年底止年度股東應佔溢利按年下跌 45 至 60%；2024 年度錄得股東應佔溢利 10.61 億港元。 | [Link](https://longbridge.com/en/news/276431030.md) | | 中國環球資產管理有限公司持有價值 1025 萬美元的阿斯利康股份 $AZN | 中國泛華資產管理有限公司在第三季度減少了對阿斯利康製藥的持股比例，下降了 10.4%，目前持有 133,580 股，市值為 1025 萬美元。這使得阿斯利康佔其總持股的 0.8%。其他對沖基金也調整了他們的持倉，幾家顯著增加了他們的持股比例 | [Link](https://longbridge.com/en/news/276435119.md) | | 阿斯利康稱，美國 FDA 已批准 Calquence 組合療法用於特定血癌患者 | 阿斯利康表示，美國 FDA 批准 Calquence 聯合療法用於某些血癌患者 | [Link](https://longbridge.com/en/news/276444179.md) | | 安大略教師養老金計劃委員會出售了阿斯利康公司（AstraZeneca PLC）的$AZN 股票 | 安大略教師退休金計劃委員會在第三季度將其在阿斯利康（AstraZeneca PLC，NASDAQ:AZN）的持股減少了 41%，目前持有 817,880 股，價值 6270 萬美元。其他機構投資者也調整了他們的持倉，加拿大帝國商業銀行世界市 | [Link](https://longbridge.com/en/news/276339476.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.